The AI software reportedly facilitates ease of use and improved accuracy in fetal ultrasound evaluations.
The Food and Drug Administration (FDA) has granted 510(k) clearance for an emerging artificial intelligence (AI)-enabled software to enhance fetal ultrasound assessment.
The DeepEcho AI software provides biometric measurement calculations through automated segmentation of anatomical landmarks, according to DeepEcho.
Emphasizing ease of use and accessibility for clinicians, DeepEcho said its recently FDA-cleared AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. (Image courtesy of DeepEcho.)
Emphasizing ease of use and accessibility for clinicians, DeepEcho said the AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. Through selection of the appropriate planes and suggested measurements, the AI software facilitates greater than 95 percent accuracy, according to DeepEcho.
"This milestone underscores the power of combining AI with clinical expertise to solve some of the most critical problems in healthcare," added Saad Slimani, M.D., M.S., co-founder and chief medical officer of DeepEcho. "With this FDA clearance, we are one step closer to making early, accurate prenatal diagnosis universally accessible and helping clinicians deliver better outcomes for families."
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.